Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Company strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs
-
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its...
-
Seasoned AI-Biotech veteran strengthens the company’s leadership in AI and mitochondrial medicine Co-Inventor of AI platform boosts company’s momentum in advancing late-stage assets to...
-
BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development.The Company plans to seek guidance in Q3 2025 from...
-
BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025